At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
PF-06882961 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-06882961 IN CHINESE ADULTS WITH TYPE 2 DIABETES MELLITUS
In Brief
A Phase 1 clinical trial evaluating PF-06882961 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJul 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedMay 17, 2021
Enrollment StartJul 7, 2021
Primary CompletionFeb 17, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.1 years ago
Interventions
PF-06882961drug
Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
Placebodrug
3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)